نتایج جستجو برای: interferon β 1a
تعداد نتایج: 272193 فیلتر نتایج به سال:
Background: It has been reported that liver function alterations occur in 8–38% of patients with relapsing-remitting multiple sclerosis (RRMS) treated with interferon-beta in controlled clinical trials or in prospective but non-controlled studies. We report herein a case of symptomatic liver dysfunction associated with two-year-period of regular interferon-beta-1a (Avonex®) intramuscular inje...
background: available evidence shows that tetracycline family has cellular and molecular mechanisms to protect neurons and oligodendrocytes by modulating matrix metalloproteinases. we tried to compare the effectiveness of intramuscular and subcutaneous interferon beta-1a (inf-β1a) in combination with oral doxycycline among patient with relapsing remitting multiple sclerosis (rrms) and secondary...
1994). 4. PRISMS Study Group: Randomiseddouble-blind placebo-controlled study of interferon β-1a in relapsing/remittingmultiple sclerosis. PRISMS (Prevention ofRelapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) StudyGroup [see comments]. Lancet 352,1498–1504 (1998).5. Johnson KP, Brooks BR, Cohen JA et al.:Copolymer 1 reduces relapse rat...
OBJECTIVES To compare treatment persistence between two dosages of interferon β-1a in a large observational multiple sclerosis registry and assess disease outcomes of first line MS treatment at these dosages using propensity scoring to adjust for baseline imbalance in disease characteristics. METHODS Treatment discontinuations were evaluated in all patients within the MSBase registry who comm...
Objective To identify serum proteins associated with MS and affected by interferon beta treatment. Methods Plasma samples from 29 untreated relapsing-remitting patients 15 healthy controls were investigated a multiplexed panel containing 92 related to inflammation. Follow-up available 13 at 1 3 months after initiation of treatment beta-1a. Results Ten differentially expressed in patients. Five ...
Interleukin 17 (IL-17) and its receptor IL-17R1 produced by T-helper cells named Th17 are involved in the pathology of autoimmune diseases. In contrast to the at least partially explained role of IL-17 in pathology of multiple sclerosis, the significance of IL-17R in MS is unclear. Therefore we have studied the expression of IL-17R in the stable phase of multiple sclerosis treated by interferon...
Treatment of early relapsing-remitting multiple sclerosis with the lymphocyte-depleting humanized monoclonal antibody alemtuzumab (Campath [registered trade mark]) significantly reduced the risk of relapse and accumulation of disability compared with interferon β-1a in a phase 2 trial [Coles et al., (Alemtuzumab vs. interferon β-1a in early multiple sclerosis. N Engl J Med 2008; 359: 1786-801)]...
BACKGROUND Statins, widely used cholesterol-lowering agents, have also been demonstrated to have anti-inflammatory and immunomdulatory effects. OBJECTIVE To evaluate the effects of atorvastatin in combination with Interferon-β in the treatment of multiple sclerosis (MS) in a randomized controlled clinical trial. METHODS Multiple sclerosis patients were randomized independently, in a double ...
BACKGROUND Brain volume atrophy is observed in relapsing-remitting multiple sclerosis (RRMS). METHODS Brain volume changes were evaluated in 23 patients with RRMS treated with interferon β-1a 44 μg given subcutaneously (SC) three times a week (tiw) and 15 healthy controls. Percentages of whole brain and tissue-specific volume change were measured from baseline (0 months) to 3 months, from 3 t...
In vivo pharmacology and toxicology evaluation of polyethylene glycol-conjugated interferon beta-1a.
Human interferon (IFN) β has well established beneficial effects in treating relapsing forms of multiple sclerosis, but current first-line treatment requires frequent (from daily to weekly) parenteral administration. A 20-kDa polyethylene glycol (PEG)-conjugated IFN β-1a (PEG-IFN β-1a) is being developed to decrease the frequency of administration and improve patient convenience and compliance....
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید